Results 301 to 310 of about 176,389 (357)

NAFLD-related HCC

2021
Nonalcoholic fatty liver disease (NAFLD) is one of the major drivers for the rising trend in hepatocellular carcinoma (HCC). Over the past three decades, the incidence of both NAFLD and HCC have increased two- to threefold. It has been forecasted that the number of patients with NAFLD in the Unites States will reach 101 million by 2030; global increase
Bubu A, Banini, Arun J, Sanyal
openaire   +2 more sources

Epidemiological Features of NAFLD From 1999 to 2018 in China

Hepatology, 2020
With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disorder in China but has not received sufficient attention.
Jiang-Hua Zhou, Feng Zhou, Wenxin Wang, Xiao-Jing Zhang, Yan-Xiao Ji, Peng Zhang, Zhi-Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li   +9 more
semanticscholar   +1 more source

NAFLD 2020: The State of the Disease.

Gastroenterology, 2020
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with a worldwide prevalence of 25%. In the US, NAFLD and its subtype, nonalcoholic steatohepatitis (NASH), affect 30% and 5% of the population, respectively.
T. Cotter, M. Rinella
semanticscholar   +1 more source

NAFLD and NASH: etiology, targets and emerging therapies.

Drug Discovery Today
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a significant threat to human health and cause a tremendous socioeconomic burden. Currently, the molecular mechanisms of NAFLD and NASH remain incompletely understood,
Shulin Wei, Li Wang, Paul C. Evans, Suowen Xu   +3 more
semanticscholar   +1 more source

Analysis of the Sphingolipidome in NAFLD

2022
The relationship between sphingolipid levels and NAFLD pathology has been recognized for some time. Numerous studies using pharmacological and genetic approaches in vitro and in animal models of NAFLD have demonstrated that modifications to sphingolipid metabolism can attenuate various facets of NAFLD pathology. However, a more precise understanding of
David, Montefusco, Johana, Lambert, Andrea, Anderson, Jeremy, Allegood, L Ashley, Cowart   +4 more
openaire   +2 more sources

Rutin ameliorated lipid metabolism dysfunction of diabetic NAFLD via AMPK/SREBP1 pathway.

Phytomedicine
BACKGROUND In diabetic liver injury, nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. Rutin is a bioflavonoid produced by the hydrolysis of glucosidases to quercetin.
Yadi Liu, Zhongyan Sun, Ruixue Dong, Peiyu Liu, Xi Zhang, Yiran Li, Xiaoshan Lai, Hio-Fai Cheong, Yu-Wei Wu, Yi-Lin Wang, Hua Zhou, Ding-Kun Gui, You-Hua Xu   +12 more
semanticscholar   +1 more source

NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance

Journal of Clinical and Experimental Hepatology
Non-alcoholic fatty liver disease (NAFLD) is rapidly emerging as a leading etiology of chronic liver disease (CLD) in Asia. The increasing incidence of NAFLD is projected to drive a surge in NAFLD-related hepatocellular carcinoma (HCC). A notable characteristic of NAFLD-HCC is its capacity for development in individuals without cirrhosis in more than a
Jia H. Koh, Meng Wang, Hiroyuki Suzuki, Mark Muthiah, Cheng H. Ng, Daniel Q. Huang   +5 more
openaire   +2 more sources

Comparison of MAFLD and NAFLD diagnostic criteria in real world

Liver international (Print), 2020
Metabolic associated fatty liver disease (MAFLD) is a novel concept proposed in 2020, the utility of which has not been tested and validated in real world. We aimed to compare the characteristics of MAFLD and non‐alcoholic fatty liver disease (NAFLD).
Su Lin, Jiaofeng Huang, Ming-Fang Wang, Rahul Kumar, Yu-Xiu Liu, Shiying Liu, Yin-Lian Wu, Xiao-Zhong Wang, Yue-Yong Zhu   +8 more
semanticscholar   +1 more source

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD

Hepatology, 2020
Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fatty liver disease (NAFLD), and alcohol‐associated liver disease (ALD) are main causes of chronic liver disease.
James M. Paik, P. Golabi, Youssef Younossi, A. Mishra, Z. Younossi   +4 more
semanticscholar   +1 more source

The global NAFLD epidemic

Nature Reviews Gastroenterology & Hepatology, 2013
NAFLD is a clinical syndrome characterized by predominant macrovesicular steatosis of the liver. The clinical and histological phenotypes of NAFLD extend from a nonalcoholic fatty liver to NASH. Although the prevalence of NAFLD is increasing globally, and it is set to become the predominant cause of chronic liver disease in many parts of the world, the
Rohit, Loomba, Arun J, Sanyal
openaire   +2 more sources